42 completed, 13 active not recruiting, 11 recruiting, 6 terminated. 77 Phase 3, 10 Phase 2.
Follow Folinic acid: new trials by email Literature Review of Folinic acid trials Research Report on Folinic acid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature Oxaliplatin, Irinotecan, Folinic acid - Pancreatic Ductal Adenocarcinoma | Phase 3 | Recruiting | John Neoptolemos | 394 | 2026-08-17 | 2026-08-27 |
| A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer ASP2138, Pembrolizumab, Oxaliplatin - Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 570 | 2026-07-28 | 2026-10-22 |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 94 | 2026-05-13 | 2026-05-22 |
| A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer Setidegrasib, Oxaliplatin, Leucovorin - Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 614 | 2026-02-17 | 2026-09-22 |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 356 | 2025-08-21 | 2026-08-25 |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy Amivantamab, Cetuximab, Bevacizumab - Colorectal Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 700 | 2024-12-12 | 2026-09-25 |
| The Sagittarius Trial Oxaliplatin, Capecitabine, Folinic acid - Colon Cancer Stage II, Colon Cancer Stage III | Phase 3 | Recruiting | IFOM ETS - The AIRC Institute of Molecular Oncology | 700 | 2024-10-22 | 2025-08-29 |
| Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial Bevacizumab, Capecitabine, Cetuximab - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 408 | 2024-04-10 | 2026-09-24 |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014). Pembrolizumab, Lenvatinib, Cisplatin - Metastatic Esophageal Squamous Cell Carcinoma | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 863 | 2021-07-28 | 2026-08-21 |
| Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients Oxaliplatin, 85 mg/m2, 5FU; 2400 mg/m2, 5FU, 250 mg/m2 - Rectal Cancer Stage III | Phase 3 | Active not recruiting | Prof. Dr. med. Claus Rödel | 702 | 2020-11-05 | 2026-08-17 |
| Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) Olaparib, 5-FU, Bevacizumab - Metastatic Colorectal Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 335 | 2020-08-19 | 2024-10-29 |
| Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ 5-Fluorouracil, Calcium folinate, Oxaliplatin - Gastroesophageal Junction Adenocarcinoma | Phase 3 | Completed | Universitätsmedizin Mannheim | 342 | 2020-06-03 | 2026-07-07 |
| Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body Capecitabine, Fluorouracil, Leucovorin - Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8 | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 314 | 2020-05-26 | 2026-10-19 |
| Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) pembrolizumab, placebo, cisplatin - Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC) | Phase 3 | Completed | Merck Sharp & Dohme LLC | 703 | 2020-02-28 | 2026-07-22 |
| A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment Irinotecan Liposomal Injection, Oxaliplatin, 5Fluorouracil - Metastatic Adenocarcinoma of the Pancreas | Phase 3 | Completed | Ipsen | 770 | 2020-02-11 | 2026-04-20 |
| Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery Capecitabine, Fluorouracil, Leucovorin - Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8 | Phase 2 / Phase 3 | Active not recruiting | NRG Oncology | 635 | 2019-12-16 | 2025-05-07 |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Recruiting | Children's Oncology Group | 5951 | 2019-10-31 | 2026-08-25 |
| A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 6720 | 2019-07-03 | 2026-10-01 |
| Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer Biospecimen Collection, Capecitabine, Carboplatin - Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 300 | 2019-06-26 | 2026-08-24 |
Showing 20 of 77. Sign in to see all of them.
Colorectal Neoplasms (18) · Pancreatic Neoplasms (9) · Burkitt Lymphoma (8) · Colonic Neoplasms (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Lymphoma (5) · Leukemia (4) · Neoplasms (4) · Adenocarcinoma Of Esophagus (3) · Down Syndrome (3) · Esophageal Squamous Cell Carcinoma (3) · Leukemia, Biphenotypic, Acute (3) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (3) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (3) · Stomach Neoplasms (3)
Children's Oncology Group (13) · National Cancer Institute (NCI) (13) · Astellas Pharma Global Development, Inc. (3) · ECOG-ACRIN Cancer Research Group (3) · Merck Sharp & Dohme LLC (3) · NRG Oncology (3) · Federation Francophone de Cancerologie Digestive (2) · SWOG Cancer Research Network (2) · UNICANCER (2) · University of California, San Francisco (2) · 1Globe Health Institute LLC (1) · CONKO-Studiengruppe (1) · City of Hope Medical Center (1) · Eli Lilly and Company (1) · Fudan University (1)
United States (55) · Canada (33) · Australia (26) · Puerto Rico (20) · Germany (19) · France (17) · South Korea (13) · China (12) · Italy (12) · New Zealand (12) · Belgium (11) · Japan (11) · Spain (11) · Switzerland (11) · United Kingdom (11)
Afsaneh Barzi, MD (1) · Al B Benson (1) · Al Benson (1) · Alyssa T Reddy (1) · Andrea Biondi (1) · Anne L Angiolillo (1) · Barbara L. Asselin, MD (1) · Carmen J Allegra (1) · Charlie Nutting, DO (1) · Claire M Mazewski (1) · Clara Montagut (1)
PMID 37890117, PMID 39121442, PMID 26590194, PMID 29284596, PMID 36603187, PMID 38446568, PMID 40315406, PMID 42085640, PMID 15659500, PMID 15774775, PMID 17439836, PMID 18618503, PMID 19546402, PMID 20030854, PMID 20084109, PMID 20881648, PMID 21997132, PMID 22488718, PMID 22994934, PMID 23007406, PMID 23233662, PMID 23233715, PMID 23678006, PMID 24556041, PMID 24970932, PMID 25042700, PMID 25088940, PMID 25877855, PMID 26124497, PMID 26261259, PMID 26265699, PMID 26615328, PMID 27234640, PMID 27573561, PMID 27575024, PMID 27722750, PMID 27918764, PMID 28006055, PMID 29195117, PMID 29228087, PMID 29713498, PMID 29812996, PMID 30138085, PMID 30199311, PMID 30293873, PMID 30339194, PMID 30414528, PMID 30654298, PMID 30842038, PMID 30892987
U10CA098543 (11), U10CA180886 (11), U10CA180868 (5), U10CA180820 (4), U10CA021115 (3), 2014 (2), 2017 (2), 2018 (2), 2019 (2), 2015 (1), 2016 (1), 2023 (1), 2025 (1), P30CA014089 (1), P30CA033572 (1)